Cover Image
市場調查報告書

鎮壓狀態 : 開發中產品分析

Sedation - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 253662
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
鎮壓狀態 : 開發中產品分析 Sedation - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 54 Pages
簡介

所謂鎮靜狀態是抑制興奮和不安狀態的狀態。症狀有講話緩慢、也會有舌頭打結口吃、無法集中、頭暈、呼吸和心跳減慢、血壓變低等。 佁療有使用巴比妥酸衍生物和苯二氮類衍生物。

本報告提供鎮壓狀態治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括了最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

鎮壓狀態概要

治療藥的開發

  • 開發中產品;概要

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • AstraZeneca PLC
  • Drawbridge Pharmaceuticals Pty Ltd
  • Jiangsu Nhwa Pharmaceutical Corporation Ltd.
  • NanoMedex Pharmaceuticals, Inc.
  • Paion AG
  • Primex Pharmaceuticals Oy
  • The Medicines Company
  • Therakind Limited

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9507IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sedation - Pipeline Review, H2 2017, provides an overview of the Sedation (Central Nervous System) pipeline landscape.

Sedation is the depression of irritability or agitation. Symptoms include talk slowly and may slur their speech, unable to concentrate, feel dizzy, slow breathing, heart rate, blood pressure will be lower. Treatment includes barbiturates and benzodiazepines.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sedation - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Sedation (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sedation (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Sedation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Sedation (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sedation (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Sedation (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sedation (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sedation (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sedation (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sedation (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sedation (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Sedation - Overview
  • Sedation - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Sedation - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Sedation - Companies Involved in Therapeutics Development
  • Drawbridge Pharmaceuticals Pty Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Nhwa Pharmaceutical Corp Ltd
  • Paion AG
  • Primex Pharmaceuticals Oy
  • The Medicines Company
  • Therakind Ltd
  • Sedation - Drug Profiles
  • alphaxalone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • clonidine hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EL-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MDCO-700 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • midazolam hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • propofol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • remimazolam - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • remimazolam - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize GABA-A for Sedation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XK-568b - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Sedation - Dormant Projects
  • Sedation - Discontinued Products
  • Sedation - Product Development Milestones
  • Featured News & Press Releases
  • Jun 05, 2017: Primex Pharmaceuticals at Euroanesthesia 2017: Next Innovation in the Management of Pediatric Sedation
  • Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting
  • Oct 05, 2016: Primex Files for Marketing Authorization for a pediatric sedative medication
  • Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting
  • Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China
  • Sep 01, 2016: Primex Announces Phase II Results of ADV6209 at the 16th World Congress of Anesthesiologists
  • Aug 31, 2016: Primex Pharmaceuticals: Next real innovation in pediatric anesthesia since propofol
  • Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
  • Apr 11, 2016: Paion Successfully Completes Patient Recruitment In Phase III Study With Remimazolam For Procedural Sedation During Colonoscopy
  • Feb 12, 2016: Paion: US-Patent & Trademark Office Grants Substance Patent For Remimazolam Besylate
  • Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment
  • Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
  • Oct 14, 2015: Paion Receives Positive Feedback From Japanese Authority PMDA About Production Of Remimazolam For Japan
  • Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia
  • Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Sedation, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Sedation - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2017
  • Sedation - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
  • Sedation - Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H2 2017
  • Sedation - Pipeline by Paion AG, H2 2017
  • Sedation - Pipeline by Primex Pharmaceuticals Oy, H2 2017
  • Sedation - Pipeline by The Medicines Company, H2 2017
  • Sedation - Pipeline by Therakind Ltd, H2 2017
  • Sedation - Dormant Projects, H2 2017
  • Sedation - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Sedation, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top